Skip to content

Ritlecitinib

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: litfulo, PF-06651600, ritlecitinib tosylate

OnpEMA approvedFDA approvedPMDA approvedATC L04AF08

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ritlecitinib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 9 molecular targets, including ITK, JAK3 and TXK. Recorded indications include Alopecia areata.

  • Approval status: onp (first approved 2023 by the FDA).
  • Molecular targets: ITK, JAK3, TXK and BMX (9 listed in DrugCentral).
  • Indications: Alopecia areata.
  • ATC code: L04AF08 (Janus-associated kinase (JAK) inhibitors).
  • Molecular formula: C15H19N5O; molecular weight 285.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Alopecia areata

Mechanism & targets

Molecular targets (9)

TargetGeneActionActivity
Tyrosine-protein kinase ITK/TSKITKunknownKi 7.57
Tyrosine-protein kinase JAK3JAK3inhibitorIC50 7.48
Tyrosine-protein kinase TXKTXKunknownKi 6.88
Cytoplasmic tyrosine-protein kinase BMXBMXunknownKi 6.26
Tyrosine-protein kinase TecTECunknownIC50 6.23
Tyrosine-protein kinase BTKBTKunknownIC50 6.22
Tyrosine-protein kinase JAK1JAK1inhibitorIC50 5.79
Tyrosine-protein kinase BlkBLKunknownIC50 4.72
Receptor tyrosine-protein kinase erbB-4ERBB4unknownIC50 4.60

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2023-09-15EMA—PFIZER EUROPE MA EEIG
2023-06-26PMDA—Pfizer Japan Inc.
2023-06-23FDA—PFIZER INC

ATC classification

ATC codeTherapeutic hierarchy
L04AF08ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Drug ineffective324.5
Therapeutic product effect incomplete298.6
Condition aggravated128.1
Acne81.7
Blood creatine phosphokinase increased75.8
Product dose omission issue56.7
Off label use51.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ritlecitinib is on its molecule page.

Molecular formulaC15H19N5O
Molecular weight285.35 g/mol
CAS number1792180-81-4
InChIKeyCBRJPFGIXUFMTM-WDEREUQCSA-N
PubChem CID118115473
C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ritlecitinib used for?

DrugCentral lists the following indications for Ritlecitinib: Alopecia areata.

How does Ritlecitinib work?

Its molecular targets in DrugCentral include ITK, JAK3 (inhibitor), TXK and BMX.

When was Ritlecitinib first approved?

Ritlecitinib was first approved by the FDA in 2023.

What is the chemical formula of Ritlecitinib?

Ritlecitinib has the molecular formula C15H19N5O and a molecular weight of 285.35 g/mol.

Browse: all drugs starting with R · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2023-06-23
AgencyFDA
Targets9
Indications1
FormulaC15H19N5O
DrugCentral ID5728
Interactive profile